Table 2.
Analysis of factors influencing the occurrence of adverse muscle symptoms in SG.
| Variables | Muscle symptoms |
|||||
|---|---|---|---|---|---|---|
| Muscle pain |
Muscle weakness |
|||||
| Mild | Moderate | Severe | Yes | No | ||
| Age (Mean ± S.D.) | 59,5 ± 10,5 | 64,2 ± 8,4 | 71,7 ± 12,6 | 70,1 ± 11,8 | 61,1 ± 10,8 | |
| p-value | 0,04* | 0,03* | ||||
| Gender N (%) |
Females | N = 8 (24,2) |
N = 5 (15,1) |
N = 1 (3,0) |
N = 4 (12,1) |
N = 10 (30,3) |
| Men | N = 1 (3,03) |
N = 3 (9,1) |
N = 15 (45,5) |
N = 16 (48,5) |
N = 3 (9,1) |
|
| p-value | 0,0002* | 0,006* | ||||
| Overweight N (%) |
(BMI ≥ 25) | – | N = 1 (3,0) |
N = 4 (12,1) |
N = 5 (15,2) |
– |
| No | N = 9 (27,3) |
N = 7 (21,2) |
N = 12 (36,4) |
N = 15 (45,4) |
N = 1 (39,4) |
|
| p-value | 0,25 | 0,24 | ||||
| Type of statin N (%) |
Atorvastatin | N = 3 (9,1) | – | N = 3 (9,1) |
N = 3 (9,1) |
N = 3 (9,1) |
| Lovastatin | N = 2 (6,1) |
– | – | – | N = 2 (6,1) |
|
| Rosuvastatin | – | N = 2 (6,1) |
N = 2 (6,1) |
N = 3 (9,1) |
N = 1 (3,0) |
|
| Simvastatin | N = 4 (12,1) |
N = 6 (18,2) |
N = 11 (33,3) |
N = 14 (42,4) |
N = 7 (21,2) |
|
| p-value | 0,21 | 0,3 | ||||
| Severity of other COVID-19 symptoms: N (%) |
Mild | N = 2 (6,1) |
N = 7 (21,2) |
N = 4 (12,1) |
N = 7 (21,2) |
N = 6 (18,2) |
| Moderate | N = 1 (3,0) |
N = 1 (3,0) |
N = 9 (27,3) |
N = 9 (27,3) |
N = 2 (6,1) |
|
| Severe | N = 1 (3,0) |
– | N = 2 (6,1) |
N = 2 (6,1) |
N = 1 (3,0) |
|
| None | N = 5 (15,2) |
– | N = 1 (3,0) |
N = 2 (6,1) |
N = 4 (12,1) |
|
| p-value | 0,01* | 0,06 | ||||
| CpK level N (%) |
Normal | N = 5 (15,2) |
N = 2 (6,1) |
N = 2 (6,1) |
N = 4 (9,1) |
N = 5 (15,2) |
| Elevated | – | N = 1 (3,0) |
N = 8 (24,2) |
N = 8 (18,2) |
N = 1 (3,0) |
|
| High | – | – | N = 5 (15,2) |
N = 5 (15,2) |
– | |
| Lack of data | N = 4 (9,1) |
N = 5 (15,2) |
N = 1 (3,0) |
N = 3 (9,1) |
N = 7 (21,2) |
|
| p-value | 0,0002* | 0,06 | ||||
| Hypertension N (%) |
Yes | – | N = 2 (6,1) |
N = 4 (9,1) |
N = 7 (21,2) |
N = 2 (6,1) |
| No | N = 9 (27,3) |
N = 6 (18,2) |
N = 9 (27,3) |
N = 13 (39,4) |
N = 11 (33,3) |
|
| p-value | 0,06 | 0,35 | ||||
| Indication for the statin use N (%) |
H | N = 9 (27,3) |
N = 5 (15,2) |
N = 14 (42,4) |
N = 17 (51,5) |
N = 11 (33,3) |
| HFH | – | N = 2 (6,1) |
N = 1 (3,0) |
N = 2 (6,1) |
N = 1 (3,0) |
|
| PCE | – | N = 1 (3,0) |
N = 1 (3,0) |
N = 1 (3,0) |
N = 1 (3,0) |
|
| p-value | 0,1 | 0,95 | ||||
Abbreviations used: CpK- Creatine kinase; H – Hypercholesterolaemia; HFH - Homozygous familial hypercholesterolaemia; PCE - Prevention of cardiovascular events.